Home   Sitemap   Contact Us
 
Hot Topics

Genescient Receives Additional Angel Funding

December 17, 2009 by admin  

Comments Off

Irvine, CA, December 17, 2009 — Genescient Corporation, a California genomic-health biotechnology company, received $500,000 in new angel investment, to help commercialize the company’s technology and to fund further research.

The investment was made by private investors with an interest in the rapidly growing field of nutrigenomics, based on the science of epigenetics and its promise of healthy life extension. A spokesman for the investors, Douglas Arends, stated: “We are especially interested in the genomics work Genescient has completed to identify human genes of aging.  This knowledge, gained from decades of selective breeding of model animals for longevity,  will to lead to the production of nutrigenomic compounds in 2010.  The plan is to build on this work and, in later years, to develop drugs aimed at treating age-associated chronic diseases and provide patients with healthy life extension. We are predicting that Genescient will become a leader in its field, with the knowledge that it now has providing it with a significant head start”.”

Damian Crowe, CEO of Genescient, said “The angel investment enables Genescient to further exploit the treasure trove of human genomic targets it currently owns,  the goal being to offer better genomic information and superior health-enhancing products to its clients.”

About Genescient Corporation:

Genescient Corporation is a California evolutionary genomics company.  Its technology is based on the genomics of model organisms selectively bred for health and longevity over 30 years.  This genomic information is combined with whole-genome data, and massive clinical databases to identify, screen and develop benign therapeutic substances for the treatment of the chronic aging-associated diseases including cardiovascular disease, Type II diabetes, and neurodegenerative diseases. Genescient will also provide its clients with genomic information services that address the genes responsible for the complex genomic trait “rate of aging”.

Contact:

Damian Crowe, CEO
Genescient Corporation
+1 949-333-0058 x3305

http://Genescient.com

Genescient Chairman to Speak at Singularity Summit 2009

August 24, 2009 by admin  

Comments Off

Singularity Summit 2009Irvine, CA, August 24, 2009 — Gregory Benford, Chairman of the Board of Genescient Corporation, will speak at the Singularity Summit 09. The Singularity Summit is a gathering of visionaries in business, science, technology, design, and the arts, coming together to explore the rising impact of science and technology on society. This year’s Summit will take place on October 3 and 4 in Manhattan, and marks the first time that the Singularity Summit will be held on the East coast.

Benford will present on Genescient’s revolutionary approach to extended human longevity, with contiguous enhancements of vigor and function. Genescient is a California systems biology company founded on the use of artificial biological selection to cure the diseases of aging. Genescient’s laboratory animals were selectively bred for longevity over 750 generations – the equivalent of 15,000 human years.

The company’s approach addresses the complex genomic networks that underlie aging and aging-associated diseases such as cardiovascular disease, Type II diabetes and neurodegenerative diseases. Benford will discuss some of the company’s latest results and its upcoming products.

The Singularity Summit was founded by Tyler Emerson, Ray Kurzweil and Peter Thiel. Its objective is to to further understanding and discussion about the Singularity concept and the future of human technological progress.

Benford, a well-known scientist, author and innovator, retired from the University of California, Irvine’s Physics department to co-found Genescient. His presentations are scheduled for 10:15 AM and 1:35 PM, Sunday, October 4.

Learn more about The Singularity Summit 2009 here:

http://www.singularitysummit.com/

About Genescient Corporation:

Genescient Corporation is a California systems biology company using advanced information technology to study the genomics of aging and age-associated disease. Genescient applies 21st century genomic technology to identify, screen and develop benign therapeutic substances for the treatment of the chronic diseases of aging including cardiovascular disease, Type II diabetes, and neurodegenerative diseases.

Contact:

Damian Crowe, CEO
Genescient Corporation
+1 949-333-0058 x3305

http://Genescient.com

###

Caffeine Cuts Male Mating Success

August 19, 2009 by admin  

Comments Off

 
Genescient study suggests that, when long-term effects are considered, two commonly ingested stimulants are not created equal. The study compares the effects of two stimulants and two sedatives.

PLoS ONEIrvine, CA, August 19, 2009 – What long-term effect does your daily cup of “morning Joe” have on your body?  In a study just published in PLoS One scientists at Genescient Corporation, a California biotechnology company, sought to answer that question.  The study evaluated the long-term health effects of two stimulants — coffee and chocolate — and two sedatives — valproic acid and lithium.

Caffeine is one of the most widely consumed drugs in the world.  It is found in coffee, tea, chocolate, colas and, more recently, “high-energy” drinks.  A Johns Hopkins University study on caffeine stated that “in North America, 80-90% of adults report regular use of caffeine.”  Most consumers of caffeine generally take it to increase their alertness and wakefulness.  Genescient scientists sought to determine  whether this increased wakefulness is accompanied by enhanced performance, and whether caffeine had any long-term health benefits.

Any lifelong human study is complicated by lifestyle choices, such as exercise and alcohol consumption, or functional demands, such as late-night driving.   To avoid the uncertainty introduced by these external factors, Genescient opted to use the well-studied Drosophila melanogaster, the laboratory fruit fly, as its model organism.  The tests measured the long-term functional effects of caffeine on both survival and reproductive functions throughout adult life.

When people consume coffee, they generally feel “up” and “ready to go.”  But is this effect a subjective illusion?  Consider mating; one of the most demanding things that a male Drosophila ever does.  It was no surprise to scientists that lithium depressed male mating success; lithium is known to suppress activity.  Surprisingly, caffeine also consistently impaired mating success in Genescient’s experiments.  By contrast, at normal doses theobromine (the chief stimulant in chocolate) was benign.  Worse still, caffeine impaired survival and female reproduction.  Again, theobromine proved relatively benign for survival and reproduction.

Lest they be tempted to celebrate, chocolate lovers should be aware that chocolate also contains caffeine.  Still, consumption of chocolate should provide the stimulative effects of theobromine without the negative effect of high doses of caffeine.  The test results show that the less caffeine the model animals consumed, the better they did.

While Drosophila aren’t people, and the results obtained in model animals may not necessarily carry over to humans, many of the important developmental and metabolic pathways are shared by both species.  With this in mind, Genescient’s results suggest that caffeine consumers might want to think twice before drinking that 4th cup of coffee or loading up on energy drinks for that all-night study session.

Interested readers can access the complete results online at:  http://www.plosone.org/article/info:doi/10.1371/journal.pone.0006578

About Genescient Corporation:

Genescient Corporation is a California systems biology company using advanced information technology to study the genomics of aging and age-associated disease. Genescient applies 21st century genomic technology to identify, screen and develop benign therapeutic substances for the treatment of the chronic diseases of aging including cardiovascular disease, Type II diabetes, and neurodegenerative diseases.   Genescient does not now market, produce, or develop therapeutics containing any of the substances tested in the publication described in this press release.

Contact:

Damian Crowe, CEO
Genescient Corporation
+1 949-333-0058 x3305
http://Genescient.com

###

Genescient and Kronos Announce Alzheimer’s Disease Collaboration

March 4, 2009 by admin  

Comments Off

Genescient Corporation and Kronos Science Laboratory will work together to analyze the Kronos Alzheimer’s Case-Control Database, considered to be the finest Alzheimer’s Disease genetic data set in the US. The companies hope to identify genes previously unrecognized genes that are involved in Alzheimer’s Disease.
PET scan of a human brain with Alzheimer's disease

PET scan of a human brain with Alzheimer's disease / NIA

Irvine, CA, March 04, 2009 — Genescient Corporation (“Genescient”) and Kronos Science Laboratory, Inc. (“Kronos”) have entered into a collaborative agreement. Genescient will use its proprietary genomic technology to analyze Kronos’ Alzheimer’s Case-Control data set. The companies hope to identify genes that may be involved in Alzheimer’s Disease, but have yet to be recognized. The Kronos Alzheimer’s data is considered to be the highest quality Alzheimer’s Disease genetic data set in the US.

A recent study by Johns Hopkins University estimates that in 2006, Alzheimer’s Disease affected 26.6 million people worldwide. This number is expected to quadruple by 2050. The Alzheimer’s Association estimates that “the direct costs to Medicare and Medicaid for care for people with Alzheimer’s and other dementias and the indirect costs to business for employees who are caregivers of persons with Alzheimer’s and other dementias amount to more than $148 billion annually.”

Genescient has already identified over 750 unique human genomic pathways that may be associated with the diseases of aging; of these, it has verified over one hundred. These pathways are implicated in cardiovascular disease, Diabetes Type II, and other chronic diseases. Genescient will use its knowledge of the pathways it has discovered, to probe the Kronos Alzheimer’s Disease data set.

Genescient’s approach is a marked departure from the standard method of identifying correlation between genes and disease. Whereas conventional approaches seek to identify individual genetic pathways responsible for disease, modern biology has demonstrated that single genetic pathway diseases are the exception. Most diseases, particularly the aging-related diseases that Genescient is concerned with, are caused by complex interactions within genomic networks.

While other approaches see only small parts of the genomic networks responsible for a disease, Genescient’s technology enables researchers to probe the entire biochemical machinery behind chronic diseases. This insight puts Genescient at the leading edge of a revolution in medicine that may ultimately lead to effective treatments for aging, the disorder that ultimately kills most of us.

About Genescient Corporation:

Genescient Corporation is a California genomics company specializing in the discovery and screening of therapeutic substances for the treatment of the chronic diseases of aging.

About Kronos Science Laboratory, Inc.:

Kronos Science Laboratory is dedicated to the discovery and commercialization of innovative new technologies for the improvement of human health and longevity. Kronos also operates the Kronos Longitudinal Aging Study (“KLAS”).

Contact:

Damian Crowe, CEO
Genescient Corporation
+1 949-333-0058 x3305
http://Genescient.com

Recent News

AIs, Superflies, and the Path to Immortality

Interpretation of genetic data from fruit flies bred for longevity suggests the major culprit [behind poor health, disease and limited [...]

Read Full Article »
Genescient Receives Additional Angel Funding

Genescient Corporation, a California genomic-health biotechnology company, received $500,000 in new angel investment, to help commercialize the company’s technology and to fund further research.

Read Full Article »

Recent Publications

Adaptation, Aging, and Genomic Information

Aging is not simply an accumulation of damage or inappropriate higher-order signaling. Aging occurs because of the extensive absence of adaptive genomic information

Read Full Article »
Evolution of ageing since Darwin

Evolutionary biology provides the only cogent, formally developed, and experimentally corroborated theory for biological ageing. In this essay, we supply a brisk run through the highlights of evolutionary research on the biology of ageing.

Read Full Article »